Investigating Arrowhead Research Corp.

Arrowhead Shareholder Alert — National Securities Law Firm Announces Investigation Of Arrowhead For Potential Violations Of Federal Securities Laws

October 9, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating potential federal securities law claims against Arrowhead Research Corp. (NASDAQ: ARWR) (“Arrowhead” or the Company”) on behalf of Arrowhead shareholders.

On October 8, 2014, Arrowhead released disappointing data from its experimental hepatitis B therapy ARC-520. On that same day, it was reported that Arrowhead, however, knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded 0.2-log and 0.3-log reductions in hepatitis B viral load. Yet, despite this knowledge, Arrowhead allegedly misled investors to believe that ARC-520 was more potent and achieved viral load reductions in the range of 0.7 log or higher.

On this news, shares of Arrowhead Research fell $5.48 per share, or over 43%, to close at $7.03 per share on October 8, 2014.

If you are a shareholder of Arrowhead and suffered significant losses on your investment and would like additional information regarding this investigation and how you may be eligible to recover your losses, please contact us toll free at 1-800-511-7037 or contact us via our website.

Tripp Levy PLLC represents individual and institutional shareholders and, along with its affiliates, has recovered billions of dollars for shareholders in similar actions around the globe. Tripp Levy PLLC is affiliated with the law firm Milberg LLP. The National Law Journal has named Milberg one of the “50 Elite Trial Lawyer Firms.” Attorney advertising. Prior results do not indicate a similar outcome.


^